Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $201 | $143 | $105 | $213 |
| G&A Expenses | $63 | $45 | $31 | $25 |
| SG&A Expenses | $63 | $45 | $31 | $25 |
| Sales & Mktg Exp. | $0 | -$1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $263 | $188 | $136 | $237 |
| Operating Income | -$263 | -$188 | -$136 | -$237 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $20 | -$47 | $5 | $0 |
| Pre-Tax Income | -$244 | -$236 | -$131 | -$237 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$244 | -$236 | -$131 | -$237 |
| % Margin | – | – | – | – |
| EPS | -1.53 | -1.49 | -0.86 | -1.56 |
| % Growth | -2.7% | -73.3% | 44.9% | – |
| EPS Diluted | -1.53 | -1.49 | -0.86 | -1.56 |
| Weighted Avg Shares Out | 159 | 159 | 152 | 152 |
| Weighted Avg Shares Out Dil | 159 | 159 | 152 | 152 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $17 | $5 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$263 | -$188 | -$135 | -$237 |
| % Margin | – | – | – | – |